We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+20.66%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.64B
AUM Growth
+$352M
Cap. Flow
-$18.8M
Cap. Flow %
-0.71%
Top 10 Hldgs %
38.92%
Holding
218
New
26
Increased
62
Reduced
55
Closed
4

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$14M
2
JNJ icon
Johnson & Johnson
JNJ
+$13.4M
3
ABT icon
Abbott
ABT
+$12.5M
4
MIST icon
Milestone Pharmaceuticals
MIST
+$12.4M
5
CI icon
Cigna
CI
+$12M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$146M
2
UNH icon
UnitedHealth
UNH
+$23.1M
3
ISRG icon
Intuitive Surgical
ISRG
+$9.43M
4
HUM icon
Humana
HUM
+$9.27M
5
ZTS icon
Zoetis
ZTS
+$7.29M

Sector Composition

Rank Sector Weight
1 Healthcare 94.16%
2 Real Estate 3.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGMO
176
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1.25M 0.05%
+149,835
New +$1.38M
MDGL icon
177
Madrigal Pharmaceuticals
MDGL
$11.4B
$1.22M 0.05%
13,340
– –
SNR
178
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$1.21M 0.05%
158,047
– –
EIDX
179
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$1.15M 0.04%
+20,000
New +$990K
FOMX
180
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1M 0.04%
300,781
– –
IMGN
181
DELISTED
Immunogen Inc
IMGN
$859K 0.03%
168,190
– –
NTLA icon
182
Intellia Therapeutics
NTLA
$1.55B
$808K 0.03%
55,050
– –
WVE icon
183
Wave Life Sciences
WVE
$1.11B
$802K 0.03%
100,012
-22,539
-18% -$553K
AXNX
184
DELISTED
Axonics, Inc. Common Stock
AXNX
$779K 0.03%
+28,100
New +$671K
MOR
185
DELISTED
MorphoSys AG American Depositary Shares
MOR
$692K 0.03%
+19,390
New +$579K
ZYME icon
186
Zymeworks
ZYME
$1.67B
$691K 0.03%
15,192
– –
UHT
187
Universal Health Realty Income Trust
UHT
$608M
$674K 0.03%
+5,742
New +$654K
RUBY
188
DELISTED
Rubius Therapeutics, Inc
RUBY
$650K 0.02%
+68,373
New +$661K
CHCT
189
Community Healthcare Trust
CHCT
$530M
$639K 0.02%
+14,900
New +$679K
PBYI icon
190
Puma Biotechnology
PBYI
$402M
$624K 0.02%
71,340
– –
CDTX
191
DELISTED
Cidara Therapeutics
CDTX
$610K 0.02%
7,939
– –
MTEM
192
DELISTED
Molecular Templates, Inc.
MTEM
$592K 0.02%
2,821
-6,786
-71% -$975K
CYH icon
193
Community Health Systems
CYH
$391M
$591K 0.02%
203,935
– –
PRGO icon
194
Perrigo
PRGO
$1.43B
$559K 0.02%
10,818
– –
MYGN icon
195
Myriad Genetics
MYGN
$507M
$512K 0.02%
18,805
– –
CLSD
196
DELISTED
Clearside Biomedical
CLSD
$479K 0.02%
11,022
– –
TRIL
197
DELISTED
Trillium Therapeutics Inc.
TRIL
$459K 0.02%
446,099
– –
SPPI
198
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$417K 0.02%
114,670
– –
GMAB icon
199
Genmab
GMAB
$17.6B
$369K 0.01%
+16,520
New +$361K
YMAB
200
DELISTED
Y-mAbs Therapeutics
YMAB
$354K 0.01%
+11,326
New +$335K
5 6 7
8
9

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Tekla Capital Management held 218 positions worth $2.64B, up 15% from $2.29B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q4 2019 filing shows 26 new, 62 increased, 55 reduced and 4 closed positions. Its largest new stake was Centene: 149,526 shares worth $9.4M. The largest sale was Celgene Corp, an estimated $146M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q4 2019 buy was Centene: 149,526 shares worth $9.4M.
  • Tekla Capital Management added most to Regeneron Pharmaceuticals in Q4 2019, an estimated $14M increase.
  • Tekla Capital Management's biggest Q4 2019 reduction was UnitedHealth, cutting an estimated $23.1M.
  • Tekla Capital Management fully exited Celgene Corp in Q4 2019, selling an estimated $146M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.64B portfolio in Q4 2019.
  • Tekla Capital Management opened 26 new positions and closed 4 in Q4 2019.
  • Tekla Capital Management's portfolio value rose 15% quarter-over-quarter to $2.64B.

Based on Tekla Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.